An interventional study of Midline insertion in Vascular Access Complication and Vascular Access Device Complications, sponsored by Hospital General Universitario de Valencia. Completed at 1 site in Spain. Per ClinicalTrials.gov, last updated 2022-08-23.
Sponsored by Hospital General Universitario de Valencia · Not applicable, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The study aims to evaluate the rate of complications and the duration of cannulation of a midline intravenous catheter compared to a short peripheral catheter in patients hospitalized in an Internal Medicine service of a Spanish hospital.
A randomized, longitudinal experimental study is designed, which will allow comparisons to be made between the results obtained in the experimental group and the control group.
The study will be carried out in the Internal Medicine and medium and long stay unit of the CHGUV, during the period of time necessary to complete the required sample size, which has finally been established at six months.
When the patient is admitted to our unit, a number is assigned from the admission service, based on their admission order; this number will serve for subsequent random assignment to one another group. In this case, the use of a website to generate said numbers is proposed.
Using established procedures for the generation of random numbers, the numbers that correspond to the subjects that are going to be part of each of the groups will be identified.
The list of random numbers that will make up the experimental group has been prepared previously by the Internal Medicine Unit secretary and will be known by the person who will carry out the placement of the midline catheter (two nurses from the unit trained in the placement and handling of this type of device, who will also be those in charge of training the rest of the staff).
The list will be reviewed daily in the morning shift, and those patients who have not given their informed consent will be eliminated, those in whom, due to their pathology, a brief admission is expected or patients who are in a terminal or palliative care situation, in those who consider the step of treatment to the subcutaneous route as the best option.
The informed consent to participate in the study will be given to the patient and/or relatives at the time of admission, also informing them that the next morning those responsible for the study will explain the object of the study in more depth and answer their questions.
Before the third day after admission, in the morning shift, the peripheral catheters will be reviewed and replaced by another peripheral catheter or by a midline catheter depending on the group to which the patient has been assigned. In case of being a patient assigned to the experimental group, the midline catheter will be placed by personnel trained for it.
The procedures for inserting and maintaining the catheters are already established in the unit and will be those that will be followed during the study, depending on the type of catheter; The care in the insertion and maintenance of midline catheters does not differ from the care of peripherally inserted central catheters, since they require a sterile technique; therefore, although the insertion of the midline catheters will be done by the selected investigators, maintenance will be performed by the unit's staff, following, as we have indicated, the procedures already established.
When the patient requires a change of venous access for whatever reason, it will be replaced by the same type of catheter (midline or conventional catheter) and the necessary information will be added to the information record sheet.
47 studies on the registry are indexed under Phlebitis; 10 are open to participants now.
This study's enrollment of 20 is below the median of 123 across 39 interventional studies indexed under Phlebitis.
Browse Phlebitis studies →Hospital General Universitario de Valencia is the lead sponsor of 11 studies on the registry; 3 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Midline catheter insertion
Device: Midline insertion
Peripheral intravenous cannulation (PIVC)
Midline catheter insertion
Length of canalization
Days of catheter stay
Time frame: Four weeks
Number of punctures
Number of times a catheter is inserted
Time frame: Four weeks
Phlebitis
Presence of catheter related phlebitis
Time frame: Four weeks
Plan to share: No
Ran from Feb 2017 to primary completion in Apr 2017, 2 months.
Of 21 non-industry interventional studies with no phase under Phlebitis, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 16. This study's 2 months is below that.
Counting every sponsor, half of 21 studies reached it within 8 months; a quarter within 5 and three quarters within 16.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Hospital General Universitario de Valencia